Latest Cellectis UCART19 data show ongoing efficacy

In a manuscript published online Wednesday in Science Translational Medicine, scientists said UCART19 from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) led to remissions within 28 days in two infants with relapsed B cell acute lymphoblastic leukemia (B-ALL). The patients were treated with the off-the-shelf T cell therapy under a compassionate use protocol.

The findings follow first-in-human data presented by Cellectis in 2015, when the company said a single pediatric B-ALL patient remained in molecular remission following UCART19 therapy and a post-treatment bone marrow transplant (see BioCentury Extra, Nov. 5, 2015)...